Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03155932 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis
A Phase 2 study, sponsored by Arena Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03155932: Clinical Trial Phase 2 study, sponsored by Arena Pharmaceuticals.
NCT03155932 is a Phase 2 study that was terminated before completion, run by Arena Pharmaceuticals. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03155932, a Phase 2 study, was terminated before completion, sponsored by Arena Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this open-label, pilot, proof of concept study is to evaluate the safety, tolerability, and efficacy of oral etrasimod (APD334) in participants with primary biliary cholangitis (PBC).
Primary Outcome
Reduction in ALP concentration is a surrogate marker of slower disease progression.
Interventions
- DRUG APD334
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-12-29 |
| Est. Completion | 2019-01-31 |
| Phase | Phase 2 |
Why NCT03155932 stopped before completion
NCT03155932 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which APD334 is the first listed.
NCT03155932 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03155932 about?
NCT03155932 is a clinical study titled "Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis". The purpose of this open-label, pilot, proof of concept study is to evaluate the safety, tolerability, and efficacy of oral etrasimod (APD334) in participants with primary biliary cholangitis (PBC).
What is the current status of trial NCT03155932?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2017-12-29. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT03155932?
The interventions under investigation include: APD334 (DRUG).
Who is sponsoring clinical trial NCT03155932?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03155932's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI